Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108
Portfolio Pulse from
Palisade Bio has reported its third quarter 2024 financial results and highlighted key accomplishments, including the commencement of enrollment and dosing in a Phase 1 clinical study of PALI-2108 for treating moderate-to-severe Ulcerative Colitis.
November 12, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Palisade Bio has started a Phase 1 clinical study for PALI-2108, targeting moderate-to-severe Ulcerative Colitis, alongside reporting its Q3 2024 financial results.
The initiation of a Phase 1 clinical study for PALI-2108 is a significant milestone for Palisade Bio, indicating progress in their lead program. This development is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100